Financial Analytics & FP&A

Financial & Revenue Analyst
who turns data into decisions

Numbers tell a story — I make sure it's the right one. I help businesses uncover growth drivers, build robust financial models, and deliver dashboards that drive executive action.

Financial Snapshot — YTD ● Live
Revenue YTD
$48.2M
▲ 12.4% YoY
Gross Margin
42.8%
▲ 1.8pp
EBITDA Margin
23.5%
▲ 2.1pp
FCF
$8.4M
▼ 3.2%
Portfolio
Financial Analysis Dashboards

A comprehensive suite of dashboards covering the full financial analysis spectrum — from revenue performance to 3-statement modeling, profitability deep-dives, and customer cohort analysis.

Revenue YTD
$48.2M
▲ 12.4%
Avg Monthly
$5.4M
▲ 8.1%
Target Hit
103.2%
▲ 5.4pp
ARR
$64.8M
▲ 15.2%
New Customers
1,284
▲ 22%
Monthly Revenue vs Target with YoY ComparisonTrend
📈
Strong outperformance. Revenue exceeded target in 7 of 9 months YTD with the largest outperformance in September (+6.6%), driven by a 22% increase in new customer acquisition. YoY growth of 12.4% significantly outpaces the prior year's 8.1% trajectory.
Revenue by DepartmentYTD
DepartmentRevenue% MixGrowthStatus
Inpatient$19,28040.0%+14.2%Strong
Outpatient$11,56824.0%+11.5%Healthy
ICU$7,23015.0%+18.4%Strong
Cath Lab$5,78412.0%+22.1%Star
Pharmacy$4,3389.0%-3.2%Declining
Total$48,200100%+12.4%
Channel Mix
Total Growth
+$7.17M
+31.0%
Price Effect
+$3.78M
53% mix
Volume Effect
+$461K
6% mix
Utilization
+$3.10M
43% mix
Mix Effect
-$175K
-2% mix
Growth Drivers Waterfall — Price vs Volume vs MixPVM Analysis
💡
Price-led growth. 53% of total growth came from pricing actions, indicating strong pricing power. However, mix effect turned negative (-$175K) due to declining premium product share — a leading indicator worth monitoring closely in Q4.
Driver Decomposition by Segment
DriverAmountContributionGrowth %
Price Effect$3,782,70053%+17%
Utilization Effect$3,105,46443%+14%
Volume Effect$461,4796%+2%
Mix / Pharmacy($175,219)-2%-1%
Total Growth$7,174,424100%+31%
Driver Mix
Revenue
$48.2M
▲ 12.4%
Gross Profit
$20.6M
▲ 16.8%
EBITDA
$11.3M
▲ 21.5%
Operating Income
$8.7M
▲ 19.2%
Net Income
$6.2M
▲ 18.4%
Income Statement — YTD vs PYCommon-Size
Line ItemCurrent% RevPYYoY
Revenue$48,200100.0%$42,884+12.4%
COGS($27,580)57.2%($25,250)+9.2%
Gross Profit$20,62042.8%$17,634+16.9%
S&M($6,750)14.0%($6,260)+7.8%
R&D($3,180)6.6%($2,815)+13.0%
G&A($1,990)4.1%($1,860)+7.0%
Operating Income$8,70018.0%$6,699+29.9%
+ D&A$2,6005.4%$2,605-0.2%
EBITDA$11,30023.4%$9,304+21.5%
Interest & Tax($2,500)5.2%($2,066)+21.0%
Net Income$6,20012.9%$5,238+18.4%
Margin Trend Analysis
Operating leverage in action. Revenue grew 12.4% but Operating Income grew 29.9% — a 2.4x leverage ratio. Gross margin expanded 180bps as cost growth (9.2%) lagged revenue growth, while disciplined S&M spending (+7.8%) reinforced margin expansion. R&D investment outpaced revenue at +13% — appropriate for sustaining future growth.
Total Assets
$78.4M
▲ 14.2%
Equity
$42.6M
▲ 17.1%
Cash
$14.2M
▲ 8.4%
D/E Ratio
0.42x
→ Stable
Current Ratio
2.18x
▲ 0.12
Balance Sheet — SummaryAs-of
ASSETS
Cash & Equivalents$14,200
Accounts Receivable$8,640
Inventory$5,820
Other Current$2,140
Current Assets$30,800
PP&E (net)$32,400
Intangibles$15,200
Total Assets$78,400
LIABILITIES & EQUITY
Accounts Payable$6,820
Short-term Debt$3,420
Other Current$3,880
Current Liabilities$14,120
Long-term Debt$15,200
Other LT$6,480
Equity$42,600
Total L+E$78,400
Cash Flow Statement — YTDReconciled
OPERATING
Net Income$6,200
+ D&A$2,600
+ Stock Comp$580
Δ Working Capital($1,420)
Cash from Operations$7,960
INVESTING
CapEx($3,200)
Acquisitions($1,800)
Cash from Investing($5,000)
FINANCING
Debt Repayment($1,200)
Dividends($650)
Cash from Financing($1,850)
Net Change in Cash$1,110
Free Cash Flow$4,760
💰
Healthy capital structure. D/E of 0.42x and Current Ratio of 2.18x indicate strong liquidity. FCF of $4.76M (60% of CFO) provides flexibility for both growth investments and shareholder returns. Working capital consumed $1.42M as growth accelerated — within expected range.
DSO
52 days
▲ 4 days
DPO
68 days
▲ 6 days
DIO
41 days
▼ 3 days
CCC
25 days
▼ 5 days
NWC
$16.7M
▲ 8.5%
Cash Conversion Cycle TrendCCC Analysis
CCC improved by 5 days YoY. The reduction is driven primarily by extending DPO from 62 to 68 days (better supplier negotiation) and lowering DIO from 44 to 41 days (improved inventory turns). DSO trending up — collections team should focus on aging buckets >60 days.
Working Capital Components
ComponentCurrentPYΔ
Accounts Receivable$8,640$7,860+$780
Inventory$5,820$5,640+$180
Prepaid Expenses$1,420$1,280+$140
Accounts Payable($6,820)($5,940)+$880
Accrued Expenses($2,420)($2,180)+$240
Net Working Capital$6,640$6,660($20)
AR Aging Analysis
Total Physicians
48
Avg Rev / Physician
$712K
▲ 8.2%
Top Specialty
Cardiology
Avg Margin
34.2%
▲ 1.8pp
Total Patients
11,640
▲ 12.4%
Revenue by SpecialtyAnnual
Top 10 Physicians by Revenue & MarginProfitability
PhysicianSpecialtyRevenueDirect CostContributionMarginPatientsStatus
Dr. A. HassanCardiology$1,420K($820K)$600K42.3%1,240Star
Dr. S. MahmoudOrthopedics$1,180K($710K)$470K39.8%980Star
Dr. M. IbrahimNeurology$1,050K($680K)$370K35.2%820Healthy
Dr. F. NabilOncology$980K($650K)$330K33.7%560Healthy
Dr. R. YoussefCardiology$920K($580K)$340K37.0%890Healthy
Dr. H. SalemInternal Med$850K($620K)$230K27.1%1,450Cash Cow
Dr. K. AdelPediatrics$720K($530K)$190K26.4%1,680Cash Cow
Dr. N. FaragGen Surgery$680K($520K)$160K23.5%420Question
Dr. L. MostafaDermatology$620K($380K)$240K38.7%1,920Healthy
Dr. W. KarimUrology$580K($420K)$160K27.6%640Question
Top 10 Total$9,000K($5,910K)$3,090K34.3%10,600
💡
Cardiology drives top performance. Dr. A. Hassan leads with $1.42M revenue at a 42.3% margin — combining high volume and premium specialty pricing. General Surgery and Urology show margin pressure (<28%) despite specialist status, suggesting either pricing review or cost optimization opportunity.
Specialty Performance Mix
SpecialtyPhysiciansRevenueAvg Margin
Cardiology8$5,840K39.8%
Orthopedics6$3,920K37.5%
Neurology4$2,840K35.2%
Oncology5$3,420K33.1%
Internal Med10$4,680K27.4%
Others15$5,500K28.2%
Revenue per Patient — Top 5
Total Budget
$46.5M
Total Actual
$48.2M
Variance
+$1.7M
+3.7%
Favorable Months
7 / 9
Monthly Budget vs Actual
🎯
Strong budget overperformance. 7 of 9 months tracked above budget with September showing the largest favorable variance (+$263K, +6.6%). Underperformance in February tied to seasonal weakness and one-time customer churn event.
Variance by Department
DepartmentBudgetActualVariance $Var %Driver
Sales$22,000$23,400+$1,400+6.4%New deals beat plan
Marketing$8,400$8,800+$400+4.8%Campaign overperformance
Operations$10,200$10,000-$200-2.0%Capacity constraint
Services$5,900$6,000+$100+1.7%In line
Total$46,500$48,200+$1,700+3.7%
FY Forecast
$66.2M
▲ 14.5%
Q4 Forecast
$18.0M
Best Case
$69.8M
Worst Case
$62.4M
12-Month Forecast with Confidence Interval3-Scenario
🔮
FY trajectory remains strong. Base case projects $66.2M (+14.5% YoY), with $7.4M spread between best/worst cases reflecting volume sensitivity. Q4 historically delivers 27-30% of annual revenue — current pipeline supports the $18M target with 85% coverage.
Key Forecast Drivers & Sensitivities
DriverBaseOptimisticConservativeSensitivity
Patient Volume Growth+8%+12%+4%High
Avg Revenue / Patient$2,450$2,600$2,300Medium
Payer Mix (Private %)62%68%58%High
Collection Rate94.3%96.0%92.0%Medium
New Services LaunchQ3Q2Q4Low
Expertise
What I Do

Core competencies across financial planning, analysis, and business intelligence.

FP&A

Budgeting, forecasting & variance analysis

3-Statement Modeling

P&L, BS, and CF integration

Growth Drivers Analysis

Price/Volume/Mix decomposition

Working Capital

CCC, DSO/DPO/DIO optimization

Profitability Analysis

Contribution margin & physician profit

Variance Analysis

Budget vs actual & root-cause analysis

Advanced Excel

Power Query, dynamic models, VBA

Power BI

DAX, data modeling & reporting

Career
Experience

Dec 2025 — Present
Revenue Analyst
Andalusia Hospitals
Leading revenue and profitability analysis across departments, specialties, and physicians. Building automated dashboards, financial models, and growth driver analyses for executive decision-making.
Revenue AnalysisFP&AGrowth DriversPower BI
March 2025 — Nov 2025
Stock Control Analyst
Andalusia Hospitals
Conducted inventory variance analysis and root cause investigations to improve stock accuracy, reduce losses, and enhance inventory control efficiency . Prepared inventory turnover, stock days, and pricing analysis reports while monitoring slow-moving items and recommending corrective actions to support profitability and cost optimization.
Variance AnalysisBudgetingCost Control
Education
Certifications

🎓

B.Sc. Accounting

Alexandria University — English Section, 2023

📜

CMA — Part 1

Certified Management Accountant — In Progress

📊

FMVA

Financial Modeling & Valuation — CFI, In Progress

Contact
Let's Work Together

Open to discussing Financial Analysis, FP&A, Modeling, and Dashboard projects.